Search Results
Oct 13, 2025, 10:00 ET RoundTable Healthcare Partners Announces Sale of Renaissance Lakewood, LLC
Germany. Terms of the transaction were not disclosed. Renaissance is a premier contract development and manufacturing organization ("CDMO") focused on nasal and injectable pharmaceutical products, including unit-dose, bi-dose, and multi-dose nasal sprays as well as small-volume parenteral
More news about: RoundTable Healthcare Partners
Oct 13, 2025, 06:00 ET LTS expands its CDMO capabilities with the acquisition of Renaissance Lakewood
capabilities in the CDMO space. Renaissance brings deep expertise, state-of-the-art manufacturing infrastructure, and a talented workforce of approximately 500 employees. This move enables LTS to offer a broader range of drug delivery solutions and strengthens its position within the CDMO community.
More news about: LTS Lohmann Therapie-Systeme AG
Oct 11, 2025, 08:45 ET C-Ray Therapeutics (Chengdu) Co., Ltd Congratulates Partner Biokin Pharmaceutical on NMPA IND Approval of First Proprietary ARC Drug [177Lu]-BL-ARC001
As a key integrator in this wave, C-Ray Therapeutics (Chengdu) Co.,Ltd has delivered over 50 CRDMO projects (35 CRO and 15 CDMO programs) covering the full lifecycle of radiopharmaceuticals—from early research and IND filing to clinical and commercial supply. With a strong
More news about: C Ray Therapeutics
Oct 10, 2025, 18:56 ET SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive
third-party manufacturing vendor"-specifically, a third-party subcontractor of Unicycive's contract development and manufacturing organization ("CDMO")-"following an FDA inspection" and that, "given the identified deficiencies, any label discussions between the FDA and the Company are precluded."
More news about: Faruqi & Faruqi, LLP
Oct 10, 2025, 09:52 ET Jubilant HollisterStier LLC launches New High-Speed Isolator based Line, at its Spokane Manufacturing Facility in the US
chains—delivering a more resilient and agile pharmaceutical manufacturing ecosystem. Commenting on the development, Chris Preti, CEO - CDMO Sterile Injectables said, "Launching our Third Line is more than a milestone for us—it's a defining moment in Jubilant HollisterStier's journey.
More news about: Jubilant HollisterStier
Oct 09, 2025, 07:00 ET Samsung Biologics Introduces Optimized Manufacturing Framework, ExellenS™
Oct. 9, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today unveiled ExellenS TM – an optimized manufacturing framework applied across the company's biomanufacturing network.
More news about: Samsung Biologics
Oct 09, 2025, 05:26 ET Europäisches Patent auf die EpyQ® AAV-Plasmid-Technologie von Ascend Advanced Therapies erfolgreich vor dem EPA verteidigt
Informationen zu Ascend: Ascend Advanced Therapies (Ascend) ist eine Gen-zu-GMP-CDMO, die sich auf die qualitativ hochwertige und kostengünstige Entwicklung und Herstellung von neuartigen Therapien spezialisiert hat. Ascend startete
More news about: Ascend Advanced Therapies (Ascend)
Oct 08, 2025, 16:30 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCY
third-party manufacturing vendor"—specifically, a third-party subcontractor of Unicycive's contract development and manufacturing organization ("CDMO")—"following an FDA inspection" and that, "given the identified deficiencies, any label discussions between the FDA and the Company are precluded."
More news about: Pomerantz LLP
Oct 08, 2025, 11:00 ET TCI Biotech Releases 2024 ESG Report, Showcasing Brand Transformation, Global Sustainability Commitments, and Award-Winning Impact
About TCI Biotech TCI Biotech (TCI Co., Ltd.) is a global leader in CDMO+ services, specializing in the research, development, and manufacturing of health foods and cosmetics. Committed to innovation and scientific excellence,
More news about: TCI; TCI Biotech
Oct 08, 2025, 09:00 ET European Patent on Ascend Advanced Therapies' EpyQ® AAV Plasmid Technology Successfully Defended at the EPO
About Ascend: Ascend Advanced Therapies (Ascend) is a gene-to-GMP CDMO specializing in high-quality, cost-effective advanced therapy development and manufacturing. Ascend launched in early 2023 with the acquisition of Freeline
More news about: Ascend Advanced Therapies (Ascend)
Oct 06, 2025, 10:23 ET Made Scientific and Streamline Bio Announce Collaboration to Accelerate AI-Driven Robotic Manufacturing for Cell Therapies
2025 /PRNewswire/ -- Made Scientific, a leading clinical and commercial-enabling cell therapy contract development and manufacturing organization (CDMO), and Streamline Bio, a next-generation autonomous robotics company solving critical challenges in cell and gene therapy (CGT) manufacturing processes,
More news about: Made Scientific, Inc.
Oct 06, 2025, 08:00 ET Matica Biotechnology Emerges as the Go-To CDMO for Cell & Gene Therapy in 2025
and regulatory needs of its partners. As a U.S.-based CDMO, Matica also offers supply chain stability and full compliance with evolving FDA guidelines—key advantages in today's CGT landscape. "We're not a one-size-fits-all CDMO," said Min Park, CCO of Matica Bio. "Our team works closely
More news about: Matica Biotechnology, Inc.
Oct 06, 2025, 07:30 ET Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities
Strengthening Scinai's CDMO Infrastructure The IIA's decision recognizes Scinai's leadership in building Israel's biopharma manufacturing infrastructure. As noted in the Israel Innovation Authority's award letter, CDMO services are essential
More news about: Scinai Immunotherapeutics Ltd.
Oct 03, 2025, 11:30 ET SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive
third-party manufacturing vendor"-specifically, a third-party subcontractor of Unicycive's contract development and manufacturing organization ("CDMO")-"following an FDA inspection" and that, "given the identified deficiencies, any label discussions between the FDA and the Company are precluded."
More news about: Faruqi & Faruqi, LLP
Oct 03, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCY
third-party manufacturing vendor"—specifically, a third-party subcontractor of Unicycive's contract development and manufacturing organization ("CDMO")—"following an FDA inspection" and that, "given the identified deficiencies, any label discussions between the FDA and the Company are precluded."
More news about: Pomerantz LLP
Oct 03, 2025, 05:58 ET Active Pharmaceutical Ingredients (API) Market to Surpass US$ 428.5 Billion by 2033 as Biotech APIs and Oncology Applications Lead Global Growth | DataM Intelligence
API businesses. Divi's Laboratories Limited Divi's leads the CDMO segment, with revenues exceeding US$ 3 billion in 2024. Its API services for global pharma giants underscore its strategic importance.
More news about: DataM Intelligence 4 Market Research LLP
Oct 02, 2025, 18:33 ET XenoSTART og Minerva Imaging udvider partnerskabet for at levere en integreret platform til udvikling af PDX-radiofarmaceutiske lægemidler
ende har en positiv effekt på de patienter, der har mest brug for dem." Minerva Imaging opererer som en fuldt integreret CRO og CDMO med speciale i radiofarmaceutiske lægemidler. Med mere end to årtiers ekspertise inden for onkologi og molekylær billeddannelse tilbyder Minerva Imaging
More news about: The START Center for Cancer Research
Oct 02, 2025, 08:01 ET XenoSTART and Minerva Imaging Expand Partnership to Deliver Integrated PDX-Radiopharmaceutical Drug Development Platform
that ultimately bring positive impact to patients who need them most." Minerva Imaging operates as a fully integrated CRO and CDMO specialized in radiopharmaceuticals. Leveraging more than two decades of expertise in oncology and molecular imaging, Minerva Imaging provides comprehensive
More news about: The START Center for Cancer Research
Oct 02, 2025, 08:01 ET XenoSTART and Minerva Imaging Expand Partnership to Deliver Integrated PDX-Radiopharmaceutical Drug Development Platform
that ultimately bring positive impact to patients who need them most." Minerva Imaging operates as a fully integrated CRO and CDMO specialized in radiopharmaceuticals. Leveraging more than two decades of expertise in oncology and molecular imaging, Minerva Imaging provides comprehensive
More news about: The START Center for Cancer Research
Oct 01, 2025, 13:37 ET Wheeler Bio Appoints Jay Benson as Chief Operating Officer
Wheeler Bio, Inc., a U.S.-based contract development and biomanufacturing organization (CDMO), announces the appointment of Jay Benson, M.B.A. as Chief Operating Officer. Benson joins Wheeler at a pivotal moment as the company scales its
More news about: Wheeler Bio, Inc.
Oct 01, 2025, 09:01 ET Primrose Bio Names Drew Burch as CEO
LifeSciences. Previously, Drew led various businesses for Thermo Fisher Scientific, including as President of three divisions: Patheon Softgels CDMO, European Drug Product CDMO, and Instrument and Enterprise Services, as leader of its Licensing and Commercial Supply business, and as VP of Strategy and Business
More news about: Primrose Bio
Sep 30, 2025, 21:00 ET tcmc、BioJapan 2025でCAR-T療法における革新技術を紹介し、日台間のがん細胞療法分野における連携促進を推進
-- 細胞・遺伝子治療（CGT）製造に特化した最先端CDMO企業である台灣細胞製造股份有限公司（tcmc）は、10月8日から10日にかけて横浜で開催される、[バイオビジネスにおけるアジア最大のパートナリングイベント- BioJapan 2025]に出展します。このイベントで、tcmc は世界クラスの CDMO サービスを紹介し、コラボレーションの促進を図るとともに、CAR-T細胞療法および再生医療の分野におけるイノベーションをアジア全域、そして世界へと広げることを目的としています。
More news about: tcmc
Sep 30, 2025, 11:45 ET Made Scientific and Syenex Forge Technology Partnership to Transform T Cell Therapy Manufacturing
organization (CDMO) specializing in the development, manufacturing, and release of autologous and allogeneic cell therapy products for clinical-and-commercial supply. Operating from two U.S.-based manufacturing facilities, Made Scientific combines the agility and entrepreneurial spirit of a specialist CDMO with
More news about: Made Scientific, Inc.
Sep 30, 2025, 10:44 ET 의료기기 제조업체 위한 엔드투엔드 서비스로 기술 격차 해소에 앞장서는 메드텍 잭슨 시 이노맥스 회장
CDMO 파트너사에게는 지식재산권(IP) 보호가 최우선 과제다. 이와 관련, 기밀 유지 접근법에 대한 질문에 시 회장은 이노맥스 메드테크가 ▲제도적 프로토콜 ▲정보 보안 조치 ▲공정 관리 ▲인력 관리 등 4대 핵심 영역을 아우르는 포괄적 기밀 유지 프로그램을 구축했다고 설명했다. 이 조치들은 예방적 통제, 실시간 모니터링, 사후 추적성을 통해 다층적 보호를 제공함으로써 고객 데이터를 보호하고 기술 독점성을 유지한다. 중국은 글로벌 CDMO 시장의 주요 참여자로서 비용
More news about: InnoMax MedTech
Sep 30, 2025, 10:20 ET Active Pharmaceutical Ingredients (API) Market to Reach USD 445.7 Billion by 2035 | Growing at a CAGR 7.15% Driving Innovation, Cost Efficiency, and Global Drug Supply Resilience
techniques improving efficiency, yield, and scalability. Contract Development & Manufacturing (CDMO) Alliances: Strategic partnerships accelerating time-to-market for innovative drugs. Green Chemistry
More news about: Vantage Market Research